Nelson Obus‘ Wynnefield Capital recently filed an amended 13D filing with the US Securities and Exchange Commission, in which reports further lowering its stake in Omega Protein Corp (NYSE:OME) to 1.06 million shares, which represent 4.7% of the company’s outstanding stock. Previously, the fund held 1.37 million shares, which accounted for 6.2% of the outstanding stock, according to its last amended 13D filing on the company.
Omega Protein is a food business company that delivers healthy nutritious products across the world, running in two divisions: human nutrition and animal nutrition. Over the past 12 months, the company’s shares have increased by 38.18%. In its last financial report for the second quarter of 2016, Omega Protein disclosed earnings per share of $0.62, topping the analysts’ estimates of $0.48, and revenue of 112.7 million, also beating the estimates of $98.9 million. At the beginning of this month, Wunderlich downgraded its rating on Omega Protein’s stock to ‘Hold’ from ‘Buy’ and raised its price target to $26 from $22, Da Davidson boosted its price target to $26 from $20, with a ‘Neutral’ rating on it, and Pivotal Research boosted its price target to $30 from $25, keeping a ‘Buy’ rating on the stock.
According to our database, there were 14 investors bullish on Omega Protein Corp (NYSE:OME) at the end of June, up by 1 from the previous quarter. Some of those hedge funds included Peter Algert and Kevin Coldiron’s Algert Coldiron Investors, with a position worth $874,000, Louis Navellier’s Navellier & Associates, which held a position valued at $284,000, and Gavin Saitowitz and Cisco J. Del Valle’s Springbok Capital.
Among new investors in Omega Protein Corp (NYSE:OME) during the second quarter were Ken Griffin’s Citadel Investment Group, which had $524,000 invested in the company, and Robert B. Gillam’s McKinley Capital Management, which acquired a position valued at $5,000.
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Wynnefield Partners Small Cap Value | 345,566 | 0 | 345,566 | 0 | 345,566 | 1.5% |
| Wynnefield Partners Small Cap Value | 577,464 | 0 | 577,464 | 0 | 577,464 | 2.6% |
| Wynnefield Small Cap Value Offshore Fund, Ltd. (No | 52,953 | 0 | 52,953 | 0 | 52,953 | 0.2% |
| Wynnefield Capital, Inc. Profit Sharing Money Purchase Plan | 85,000 | 0 | 85,000 | 0 | 85,000 | 0.4% |
| Wynnefield Capital Management | 923,030 | 0 | 923,030 | 0 | 923,030 | 4.1% |
| Wynnefield Capital, Inc. 13-3688495 | 52,953 | 0 | 52,953 | 0 | 52,953 | 0.2% |
| Nelson Obus | 0 | 1,060,983 | 0 | 1,060,983 | 1,060,983 | 4.7% |
| Joshua Landes | 0 | 1,060,983 | 0 | 1,060,983 | 1,060,983 | 4.7% |
Follow Nelson Obus And Joshua Landes's Wynnefield Capital
Page 1 of 14 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
(Amendment No. 8)
Under the Securities Exchange Act of 1934
OMEGA PROTEIN CORPORATION
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
68210P107
(CUSIP Number)
Wynnefield Partners Small Cap Value, L.P.
450 Seventh Avenue, Suite 509
New York, New York 10123
Attention: Mr. Nelson Obus
Copy to:
Jeffrey S. Tullman, Esq.
Kane Kessler, P.C.
1350 Avenue of the Americas, 26th Floor
New York, New York 10019
(212) 541-6222
(Name, Address and Telephone
Number of Person Authorized to Receive Notices and Communications)
August 23, 2016
(Date of Event which requires Filing of
this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨
